natgillin/translations-raw huggingface dataset:
Amprenavir 600 mg twice daily with ritonavir 100 mg twice daily Atazanavir 300 mg daily with ritonavir 100 mg daily Fosamprenavir 700 mg twice daily with ritonavir 100 mg twice daily Lopinavir 400 mg co-formulated with ritonavir 100 mg twice daily Saquinavir 1000 mg twice daily with ritonavir 100 mg twice daily Tipranvir 500 mg twice daily with ritonavir 200 mg twice daily Darunavir 600 mg twice daily with ritonavir 100 mg twice daily
Amprenavir 600 mg dvakrat na dan z ritonavirjem 100 mg dvakrat na dan Atazanavir 300 mg na dan z ritonavirjem 100 mg na dan Fosamprenavir 700 mg dvakrat na dan z ritonavirjem 100 mg dvakrat na dan Lopinavir 400 mg v kombinaciji z ritonavirjem 100 mg dvakrat na dan Sakvinavir 1000 mg dvakrat na dan z ritonavirjem 100 mg dvakrat na dan Tipranvir 500 mg dvakrat na dan z ritonavirjem 200 mg dvakrat na dan Darunavir 600 mg dvakrat na dan z ritonavirjem 100 mg dvakrat na dan
Paediatric use:
Pediatrična uporaba:
Lopinavir co-formulated with ritonavir is recommended for children 2 years of age and older.
Lopinavir v kombinaciji z ritonavirjem, je priporočljiv za otroke, stare 2 leti ali več.
For further dosage recommendations, refer to the product information of other Protease Inhibitors approved for co-administered with ritonavir.
Za nadaljnja priporočila o odmerjanju glejte navodilo za uporabo drugega zaviralca proteaz, odobrenega za sočasno uporabo z ritonavirjem.
2 Renal impairment:
2 Okvara ledvic:
Ritonavir should not be given as a pharmacokinetic enhancer to patients with decompensated liver disease.
Ritonavirja kot farmakokinetičnega stopnjevalca ne smejo dobiti bolniki z dekompenzirano boleznijo jeter.
In the absence of pharmacokinetic studies in patients with stable severe hepatic impairment (Child Pugh Grade C) without decompensation, caution should be exercised when ritonavir is used as a pharmacokinetic enhancer as increased levels of the co-administered PI may occur.
Zato je treba ritonavir kot farmakokinetični stopnjevalec uporabljati previdno, kajti koncentracija sočasno uporabljenega zaviralca proteaz se lahko zviša.
The recommended dosage of Norvir solution is 600 mg (7.5 ml) twice daily by mouth.
Priporočeno odmerjanje raztopine Norvir je 600 mg (7, 5 ml) peroralno dvakrat na dan.
Treatment should be initiated at 300 mg (3.75 ml) twice daily for a period of three days and increased by 100 mg (1.25 ml) twice daily increments up to 600 mg twice daily over a period of no longer than 14 days.
Zdravljenje je treba začeti s 300 mg (3, 75 ml) dvakrat na dan v obdobju 3 dni in odmerek zvečevati po 100 mg (1, 25 ml) dvakrat na dan do 600 mg dvakrat na dan v obdobju, ki ne presega 14 dni.
Paediatric use (2 years of age and above): the recommended dosage of Norvir solution in children is 350 mg/ m² by mouth twice daily and should not exceed 600 mg twice daily.
Priporočeno odmerjanje raztopine Norvir pri otrocih je 350 mg/ m2 peroralno dvakrat na dan in ne sme preseči 600 mg dvakrat na dan.
Norvir should be started at 250 mg/ m² and increased at 2 to 3 day intervals by 50 mg/ m² twice daily.
Norvir je treba na začetku uporabljati v odmerku 250 mg/ m2 in ga v presledkih od 2 do 3 dni zvečevati po 50 mg/ m2 dvakrat na dan.
When possible, dose should be administered using a calibrated dosing syringe.
Za odmerjanje je treba po možnosti uporabiti kalibrirano odmerno brizgo.
Paediatric Dosage Guidelines
Smernice za pediatrično odmerjanje
Body Surface area* (m²) 0.25 0.50 1.00 1.25 1.50
telesna površina * (m2)
* Body surface area can be calculated with the following equation BSA (m²) = √ (Height (cm) X Weight (kg) / 3600)
* Telesno površino lahko izračunamo po enačbi: telesna površina (m2). = √( višina (cm) X masa (kg) / 3600)
To calculate the volume to be administered (in ml) the body surface area should be multiplied by a factor of:
Za izračun potrebne količine (v ml) je treba telesno površino pomnožiti z naslednjimi faktorji:
3.1 for a dose of 250 mg/ m²; 3.8 for one of 300 mg/ m²; and by 4.4 for 350 mg/ m².
3, 1 za odmerek 250 mg/ m2; 3, 8 za odmerek 300 mg/ m2 in 4, 4 za odmerek 350 mg/ m2.
Pharmacokinetic data indicate that no dose adjustment is necessary in patients with mild to moderate 3 hepatic impairment (see section 5.2).
Farmakokinetični podatki kažejo, da odmerka pri bolnikih z blago do zmerno okvaro jeter ni treba prilagajati (glejte poglavje 5. 2).
Ritonavir should not be given to patients with severe hepatic impairment (see section 4.3).
Ritonavirja ne smejo dobiti bolniki s hudo okvaro jeter (glejte poglavje 4. 3).
Pharmacokinetic data indicated that no dose adjustment is necessary for elderly patients (see section 5.2).
Farmakokinetični podatki kažejo, da prilagoditev odmerka za starejše bolnike ni potrebna.
The following medicines are contraindicated when used with ritonavir and unless otherwise noted, the contraindication is based on the potential for ritonavir to inhibit metabolism of the co-administered drug, resulting in increased exposure to the co-administered drug and risk of clinically significant adverse effects.
Če ni navedeno drugače, temelji kontraindikacija na možnosti, da ritonavir zavre presnovo sočasno uporabljenega zdravila, kar povzroči večjo izpostavljenost sočasno uporabljenemu zdravilu in tveganje za klinično pomembne neželene učinke.
For some products, contraindications may be more relevant when ritonavir is used as an antiretroviral agent than when ritonavir is used as a pharmacokinetic enhancer (eg rifabutin and voriconazole):
Za nekatera zdravila so kontraindikacije lahko pomembnejše, če je ritonavir uporabljen kot protiretrovirusno zdravilo, kot če je uporabljen kot farmakokinetični stopnjevalec (npr. rifabutin in vorikonazol):
Drug Class
Skupina zdravil
Drugs within Class
Zdravila v skupini
Concomitant Drug Levels Increased α 1-Adrenoreceptor Antagonist
Zvišanje koncentracije sočasno uporabljenega zdravila Αntagonist adrenergičnih receptorjev α1
Increased plasma concentrations of alfuzosin which may lead to severe hypotension (see section 4.5).
Zvišana koncentracija alfuzosina v plazmi, kar lahko vodi v resno hipotenzijo (glejte poglavje 4. 5)
Meperidine, piroxicam, propoxyphne
Meperidin, piroksikam, propoksifen
Increased plasma concentrations of normeperidine, piroxicam and propoxyphene.
Zvišana koncentracija normeperidina, piroksikama in propoksifena v plazmi.
Amiodarone, bepridil, encainide, flecanide, propafenone, quinidine
Amiodaron, bepridil, enkainid, flekanid, propafenon, kinidin
Increased plasma concentrations of amiodarone, bepridil, encainide, flecanide, propafenone, quinidine.
Zvišana koncentracija amiodarona, bepridila, enkainida, flekanida, propafenona, kinidina v plazmi.
Antifungal
4 Antimikotik
Concomitant use of ritonavir (400 mg twice daily and more) and voriconazole is contraindicated due to a reduction in voriconazole plasma concentrations and possible loss of effect (see section 4.5)
Sočasna uporaba ritonavirja (400 mg dvakrat na dan ali več) in vorikonazola je kontraindicirana zaradi znižanja koncentracije vorikonazola v plazmi in možne izgube učinka (glejte poglavje 4. 5).
Antimycobacterial
Zdravilo za zdravljenje infekcij z mikobakterijami
Concomitant use of ritonavir dosed as an antiretroviral agent (600 mg twice daily) and rifabutin due to an increase of rifabutin serum concentrations and risk of adverse events including uveitis (see section 4.4).
Sočasna uporaba ritonavirja, odmerjanega kot protiretrovirusno zdravilo (600 mg dvakrat na dan), in rifabutina zaradi zvišanja koncentracije rifabutina v serumu in tveganja za neželene učinke, vključno z uveitisom (glejte poglavje 4. 4).
Recommendations regarding use of ritonavir dosed as a pharmacokinetic enhancer with rifabutin are noted in section 4.5
Priporočila za uporabo ritonavirja, odmerjanega kot farmakokinetičnega stopnjevalca z rifabutinom, so navedena v poglavju 4. 5.
Antipsychotics/ Neuroleptics
Antipsihotiki/ nevroleptiki
Increased plasma concentrations of clozapine and pimozide.
Zvišana koncentracija klozapina in pimozida v plazmi.
Increased plasma concentrations of ergot derivatives leading to acute ergot toxicity, including vasospasm and ischaemia.
Zvišana koncentracija ergot - derivatov v plazmi s posledičnimi ergotskimi toksičnimi učinki, vključno z vazospazmom in ishemijo.
HMG Co-A Reductase Inhibitor
Zaviralec reduktaze HMG Co- A
Increased plasma concentrations of lovastatin and simvastatin; thereby, increasing the risk of myopathy including rhabdomyolysis (see section 4.5).
Zvišana koncentracija lovastatina in simvastatina v plazmi; s tem se poveča tveganje za miopatijo, vključno z rabdomiolizo (glejte poglavje 4. 5).
Sedatives/ hypnotics
5 Sedativi/ hipnotiki
(For caution on parenterally administered midazolam, see section 4.5).
(Za previdnost pri uporabi parenteralnega midazolama glejte poglavje 4. 5).
Ritonavir Drug Level Decreased Herbal Preparation
Znižanje koncentracije ritonavirja
John’ s Wort
Zeliščni pripravki
Herbal preparations containing St John’ s wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of ritonavir (see section 4.5).
Šentjanževka
5 4.4 Special warnings and precautions for use
Zeliščni pripravki s šentjanževko (Hypericum perforatum) zaradi tveganja za znižanje plazemske koncentracije in kliničnih učinkov ritonavirja (glejte poglavje 4. 5).
Ritonavir is not a cure for HIV-1 infection or AIDS.
Ritonavir ne ozdravi okužbe s HIV- 1 ali AIDS- a.
Patients receiving ritonavir or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV-1 infection.
Bolnikom, ki dobivajo ritonavir ali kakšno drugo protiretrovirusno zdravilo, se lahko še naprej pojavljajo oportunistične okužbe in drugi zapleti okužbe s HIV- 1.
Patients should be advised that current antiretroviral therapy has not been proven to prevent the risk of transmission of HIV to others through blood or sexual contact.
Bolnikom je treba povedati, da trenutno uporabljana protiretrovirusna zdravila ne preprečijo tveganja za prenos HIV na druge osebe s krvjo ali spolnim stikom.
Appropriate precautions should continue to be used.
Zato morajo še naprej uporabljati ustrezne previdnostne ukrepe.
Patients with chronic diarrhoea or malabsorption:
Bolniki s kronično drisko ali malabsorpcijo:
The relatively high frequency of diarrhoea during treatment with ritonavir may compromise the absorption and efficacy (due to decreased compliance) of ritonavir or other concurrent medications.
Razmeroma velika pogostnost driske med zdravljenjem z ritonavirjem lahko ogrozi absorpcijo in (zaradi zmanjšane sodelovalnosti bolnika) učinkovitost ritonavirja ali drugih sočasno uporabljanih zdravil.
Serious persistent vomiting and/ or diarrhoea associated with ritonavir use might also compromise renal function.
Hudo, dolgotrajno, z ritonavirjem povezano bruhanje in/ ali driska lahko poleg tega ogrozi delovanje ledvic.
Haemophilia: there have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in haemophiliac patients type A and B treated with protease inhibitors.
Pri nekaterih bolnikih s hemofilijo tipa A in B so med uporabo zaviralcev proteaz ugotavljali večjo nagnjenost h krvavitvam, vključno s spontanimi kožnimi hematomi in hemartrozami.
Diabetes mellitus and hyperglycaemia:
Diabetes mellitus in hiperglikemija:
New onset diabetes mellitus, hyperglycaemia or exacerbation of existing diabetes mellitus has been reported in patients receiving protease inhibitors.
Med zdravljenjem z zaviralci proteaz so opisani novonastala sladkorna bolezen, hiperglikemija ali poslabšanje obstoječe sladkorne bolezni.
In some of these the hyperglycaemia was severe and in some cases also associated with ketoacidosis.
Pri nekaterih bolnikih je bila hiperglikemija huda in v nekaterih primerih povezana tudi s ketoacidozo.
Many patients had confounding medical conditions, some of which required therapy with agents that have been associated with the development of diabetes mellitus or hyperglycaemia.
Številni bolniki so imeli dodatne bolezni, od katerih so nekatere zahtevale zdravljenje z zdravili, povezanimi s pojavom sladkorne bolezni ali hiperglikemije.
Lipodystrophy:
6 Lipodistrofija:
A connection between visceral lipomatosis and PIs and lipoatrophy and nucleoside reverse transcriptase inhibitors (NRTIs) has been hypothesised.
Domnevajo, da obstaja povezava med visceralno lipomatozo in zaviralci proteaz ter lipoatrofijo in zaviralci nukleozidne reverzne transkriptaze.
A higher risk of lipodystrophy has been associated with individual factors such as older age, and with drug related factors such as longer duration of antiretroviral treatment and associated metabolic disturbances.
Večje tveganje za lipodistrofijo je povezano z individualnimi dejavniki, npr. višjo starostjo, in dejavniki, povezanimi z zdravili, npr. z dolgotrajnejšim protiretrovirusnim zdravljenjem in spremljajočimi presnovnimi motnjami.
Patients who exhibit these signs or symptoms should be evaluated and Norvir therapy should be discontinued if a diagnosis of pancreatitis is made (see section 4.8).
Bolnike s temi znaki oz. simptomi je treba pregledati; če je diagnoza pankreatitisa potrjena, je treba zdravljenje z Norvirjem prekiniti (glejte poglavje 4. 8).
Immune Reactivation Syndrome: in HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymtomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Pri s HIV okuženih bolnikih s hudo imunsko pomanjkljivostjo lahko ob uvedbi kombiniranega protiretrovirusnega zdravljenja (CART - "combination antiretroviral therapy") nastane vnetna reakcija na asimptomatične ali rezidualne oportunistične patogene in povzroči resna klinična stanja ali poslabšanje simptomov.
Typically, such reactions have been observed within the first few weeks or months of 6 initiation of CART.
Take reakcije so navadno opazili v prvih nekaj tednih ali mesecih po uvedbi CART.
Ritonavir should not be given to patients with decompensated liver disease.
Ritonavirja ne smejo dobiti bolniki z dekompenzirano boleznijo jeter.
For patients with stable severe hepatic impairment (Child Pugh Grade C) without decompensation see section 4.2.
Za bolnike s stabilno hudo okvaro jeter (razred C po Child- Pughu) brez dekompenzacije glejte poglavje 4. 2.
Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse events.
Bolnike s kroničnim hepatitisom B ali C, ki dobivajo kombinirano protiretrovirusno terapijo, bolj ogrožajo hudi in potencialno smrtni neželeni učinki na jetrih.
Renal disease:
Bolezni ledvic:
Since the renal clearance of ritonavir is negligible, the decrease in the total body clearance is not expected in patients with renal impairment.
Ker je ledvični očistek ritonavirja zanemarljiv, pri bolnikih z okvaro ledvic ni pričakovati zmanjšanja celotnega telesnega očistka.
See also section 4.2.
Glejte tudi poglavje 4. 2.
Ritonavir oral solution contains alcohol (43% v/ v), ie up to 258 mg per maximum dose of 600 mg, equivalent to 65 ml beer, 27 ml wine per dose.
Peroralna raztopina ritonavirja vsebuje alkohol (43% V/ V), tj. do 258 mg na največji odmerek 600 mg, kar ustreza 65 ml piva ali 27 ml vina na odmerek.
Each 100 mg dose contains up to 43 mg alcohol and each 200 mg dose contains 86 mg alcohol.
Vsak 100 mg odmerek vsebuje do 43 mg alkohola, vsak 200 mg odmerek pa 86 mg alkohola.
Therefore concomitant administration of Norvir with disulfiram or medicines with disulfiram-like reactions (eg metronidazole) should be avoided.
Zato se Norvirja ne sme uporabljati hkrati z disulfiramom ali zdravili, ki povzročajo disulfiramu podobne reakcije (npr. metronidazol).
Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported in patients with advanced HIV-disease and/ or long-term exposure to combination antiretroviral therapy (CART).
Čeprav je vzrokov verjetno več (vključno z uporabo kortikosteroidov, uživanjem alkohola, hudo imunosupresijo, višjim indeksom telesne mase), so o primerih osteonekroze poročali zlasti pri bolnikih z napredovalo boleznijo HIV ali dolgotrajno izpostavljenostjo kombiniranemu protiretrovirusnemu zdravljenju (CART – combination antiretroviral therapy) ali obojim.
PR interval prolongation: ritonavir has been shown to cause modest asymptomatic prolongation of the PR interval in some healthy adult subjects.
Ugotovljeno je, da ritonavir nekaterim zdravim odraslim osebam zmerno in asimptomatsko podaljša interval PR.
Rare reports of 2nd or 3rd degree atrioventricular block in patients with underlying structural heart disease and pre-existing conduction system abnormalities or in patients receiving drugs known to prolong the PR interval (such as verapamil or atazanavir) have been reported in patients receiving ritonavir.
Med zdravljenjem z ritonavirjem so redko poročali o atrioventrikularnem bloku 2. ali 3. stopnje pri bolnikih, ki so imeli osnovno organsko bolezen in že obstoječe nepravilnosti prevodnega sistema, in bolnikih, zdravljenih z zdravili, ki podaljšajo interval PR (npr. verapamil ali atazanavir).
Norvir should be used with caution in such patients (see section 5.1).
Norvir morate pri takšnih bolnikih uporabljati previdno (glejte poglavje 5. 1).
The following Warnings and Precautions should be considered when ritonavir is used as an antiretroviral agent.
Če je ritonavir uporabljen kot protiretrovirusno zdravilo, je treba upoštevati naslednja opozorila in previdnostne ukrepe.
When ritonavir is used as a pharmacokinetic enhancer, full details on the warnings and precautions relevant to that particular PI must be considered, therefore the Summary of Product Characteristics, section 4.4, for the particular PI must be consulted to determine if the information below is applicable.
Preverite poglavje 4. 4 v povzetku glavnih značilnosti uporabljenega zaviralca proteaz, da boste ugotovili, ali pridejo v poštev spodaj navedene informacije.
7 PDE5 inhibitors:
Zaviralci fosfodiesteraze tipa 5 (PDE5):
Particular caution should be used when prescribing sildenafil, tadalafil or vardenafil in patients receiving ritonavir.
Posebna previdnost je potrebna pri predpisovanju sildenafila, tadalafila oz. vardenafila bolnikom, ki jemljejo ritonavir.
Co-administration of ritonavir with these medicinal products is expected to substantially increase their concentrations and may result in associated adverse events such as hypotension and prolonged erection (see section 4.5).
Pričakovati je treba, da sočasna uporaba ritonavirja in teh zdravil bistveno zviša njihovo koncentracijo in lahko povzroči z njimi povezane neželene učinke, npr. hipotenzijo in dolgotrajno erekcijo (glejte poglavje 4. 5).
HMG-CoA reductase inhibitors:
Zaviralci reduktaze HMG- CoA:
If treatment with an HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended (see section 4.5).
Če je indicirano zdravljenje z zaviralcem reduktaze HMG- CoA, sta priporočljiva pravastatin ali fluvastatin (glejte poglavje 4. 5).
Particular caution should be used when prescribing ritonavir in patients taking digoxin since co-administration of ritonavir with digoxin is expected to increase digoxin levels.
Pričakovati je namreč treba, da sočasna uporaba ritonavirja in digoksina zviša koncentracijo digoksina.
The increased digoxin levels may lessen over time (see section 4.5).
Zvišanje koncentracije digoksina se lahko sčasoma zmanjša (glejte poglavje 4. 5).
In patients who are already taking digoxin when ritonavir is introduced, the digoxin dose should be reduced to one-half of the patients’ normal dose and patient need to be followed more closely than usual for several weeks after initiating co-administration of ritonavir and digoxin.
Po začetku sočasne uporabe ritonavirja in digoksina je treba bolnike več tednov kontrolirati pogosteje kot ponavadi.
Ethinyl estradiol:
Etinilestradiol:
Glucocorticoids:
Glukokortikoidi:
Concomitant use of ritonavir and fluticasone or other glucocorticoids that are metabolised by CYP3A4 is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects, including Cushing’ s syndrome and adrenal suppression (see section 4.5).
Sočasna uporaba ritonavirja in flutikazona ali drugih glukokortikoidov, ki se presnavljajo s CYP3A4, ni priporočljiva, razen če možna korist zdravljenja odtehta tveganje 8 sistemskih učinkov kortikosteroidov, vključno s Cushingovim sindromom in adrenalno supresijo (glejte poglavje 4. 5).
Adverse events of nausea, dizziness, hypotension and syncope have been observed in single dose interaction studies in healthy volunteers (see section 4.5)
V študijah medsebojnega delovanja z enim odmerkom pri zdravih prostovoljcih so zabeležili neželene učinke: navzejo, omotico, hipotenzijo in sinkopo (glejte poglavje 4. 5).
For a description of the mechanisms and potential mechanisms contributing to the interaction profile of the PIs, see section 4.5.
Za opis mehanizmov in možnih mehanizmov, ki prispevajo k medsebojnemu delovanju zaviralcev proteaz, glejte poglavje 4. 5.
Higher doses of ritonavir have been shown to be associated with an increased incidence of adverse events.
Ugotovljeno je, da večje odmerke ritonavirja spremlja večja pogostnost neželenih učinkov.
8 Co-administration of saquinavir and ritonavir has led to severe adverse events, mainly diabetic ketoacidosis and liver disorders, especially in patients with pre-existing liver disease.
Sočasna uporaba sakinavirja in ritonavirja je povzročila hude neželene učinke, predvsem diabetično ketoacidozo in jetrne motnje, zlasti pri bolnikih z že obstoječo boleznijo jeter.
Saquinavir/ ritonavir should not be given together with rifampicin, due to the risk of severe hepatotoxicity (presenting as increased hepatic transaminases) if the three medicines are given together (see section 4.5).
Sakvinavirja/ ritonavirja ne smete dajati hkrati z rifampicinom: med sočasno uporabo teh treh zdravil namreč obstaja tveganje za hude hepatotoksične učinke (ki se pokažejo z zvišanjem jetrnih transaminaz) (glejte poglavje 4. 5).
Tipranavir: co-administered with 200 mg of ritonavir has been associated with reports of clinical hepatitis and hepatic decompensation including some fatalities.
Med sočasno uporabo tipranavirja z 200 mg ritonavirja so bili opisani primeri kliničnega hepatitisa in dekompenzacije jeter, vključno z nekaj smrtnimi primeri.
Co-administration of atazanavir with ritonavir in doses greater than 100 mg once daily has not been clinically evaluated.
Sočasna uporaba atazanavirja z ritonavirjem v odmerkih, večjih kot 100 mg enkrat na dan, ni klinično ocenjena.
The use of higher ritonavir doses might alter the safety profile of atazanavir (cardiac effects, hyperbilirubinemia) and therefore is not recommended.
Uporaba večjih odmerkov ritonavirja lahko spremeni varnostne značilnosti atazanavirja (učinki na srce, hiperbilirubinemija), zato ni priporočljiva.
Ritonavir has a high affinity for several cytochrome P450 (CYP) isoforms and may inhibit oxidation with the following ranked order:
Ritonavir ima veliko afiniteto za več izooblik citokroma P450 (CYP) in lahko zavre oksidacijo po naslednjem zaporedju:
Co-administration of Norvir and medicinal products primarily metabolised by CYP3A may result in increased plasma concentrations of the other medicinal product, which could increase or prolong its therapeutic and adverse effects.
Sočasna uporaba Norvirja z zdravili, ki se primarno presnavljajo s CYP3A, lahko poveča koncentracijo drugega zdravila v plazmi, to pa lahko poveča ali podaljša njegove terapevtske in neželene učinke.
For select medicinal products (eg alprazolam) the inhibitory effects of ritonavir on CYP3A4 may decrease over time.
Pri nekaterih zdravilih (npr. pri alprazolamu) se lahko zaviralni učinki ritonavirja na CYP3A4 sčasoma zmanjšajo.
Ritonavir also has a high affinity for P-glycoprotein and may inhibit this transporter.
Ritonavir ima tudi veliko afiniteto za P- glikoprotein in lahko zavre ta prenašalec.